Hims & Hers Health (HIMS) Rating Upgraded to Strong Buy: What You Need to Know

Understanding the Zacks Rank and Its Impact on Hims & Hers Health

Hims & Hers Health, Inc. (HIMS) has recently been upgraded to a Zacks Rank #1, which is classified as a "Strong Buy." This rating change reflects an upward trend in earnings estimates, a key factor that significantly influences stock prices. The Zacks rating system is unique because it focuses solely on a company's changing earnings picture, making it a valuable tool for investors.

The Zacks Consensus Estimate tracks EPS (Earnings Per Share) forecasts for the current and next fiscal years from sell-side analysts. This consensus measure helps investors understand how the market views a company's financial health. Since earnings estimates are a powerful driver of stock price movements, the Zacks rating system offers a more objective approach compared to traditional analyst ratings, which can be influenced by subjective factors.

Why Earnings Estimates Matter

The relationship between a company's future earnings potential and its stock price movement is well-documented. Institutional investors often use earnings and earnings estimates to determine the fair value of a company's shares. When earnings estimates increase, the perceived fair value of the stock rises, prompting institutional investors to buy or sell accordingly. These large-scale investment decisions can significantly impact stock prices.

For Hims & Hers Health, the recent upgrade to a Zacks Rank #1 indicates an improvement in the company's underlying business. Rising earnings estimates suggest that the company is performing better than previously anticipated, and this positive outlook could lead to an increase in its stock price.

Harnessing the Power of Earnings Estimate Revisions

Empirical research supports the idea that trends in earnings estimate revisions are closely linked to near-term stock movements. Tracking these revisions can be a rewarding strategy for investors. The Zacks Rank system plays a crucial role in this process by using four factors related to earnings estimates to classify stocks into five categories, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell).

This system has a proven track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. Investors looking for high-performing stocks can benefit from understanding the Zacks Rank system and its ability to identify companies with strong earnings growth potential.

Earnings Estimate Revisions for Hims & Hers Health

Hims & Hers Health is expected to earn $0.75 per share for the fiscal year ending December 2025, representing no year-over-year change. However, analysts have been steadily increasing their estimates for the company. Over the past three months, the Zacks Consensus Estimate for Hims & Hers Health has increased by 15.9%.

This upward revision in earnings estimates suggests that the company is on a positive trajectory. Investors should take note of this trend, as it could indicate a favorable investment opportunity.

The Zacks Rating System: A Balanced Approach

Unlike traditional analyst ratings, which tend to favor positive recommendations, the Zacks rating system maintains a balanced approach. At any given time, it provides an equal proportion of "buy" and "sell" ratings for its universe of over 4,000 stocks. Only the top 5% of Zacks-covered stocks receive a "Strong Buy" rating, while the next 15% get a "Buy" rating.

Being placed in the top 20% of Zacks-covered stocks indicates that a company has superior earnings estimate revision features. This makes it a strong candidate for generating market-beating returns in the near term.

Conclusion

The upgrade of Hims & Hers Health to a Zacks Rank #1 places it in the top 5% of Zacks-covered stocks in terms of estimate revisions. This position suggests that the stock may experience positive momentum in the near future. For investors seeking opportunities in the healthcare sector, Hims & Hers Health presents a compelling case based on its improved earnings outlook and the reliability of the Zacks rating system.